Summary

Bridge rounds are meant to carry a company to its next priced round. Trouble starts when nobody can yet say when that round will happen or who will lead it. This paper draws on a mandate for a North American industrial biotechnology company with a biological crop-protection platform: more than a decade old, backed by grants and paying development partners, and seeking a bridge ahead of a Series A that had no confirmed date, size or lead investor.

In my view you can't price a bridge off a round nobody has defined yet. It needs its own terms: a fixed amount with a realistic first close, a valuation cap, a maturity with a fallback, clear ranking against existing debt, and proceeds tied to milestones an investor can put a date on. With those in place the bridge can be judged on its own merits. Without them, most specialist investors will just wait for the Series A.

1. The market: selective, and with a long memory

Source: AgFunder Global AgriFoodTech Investment Report 2026.

There's still capital for agricultural biotechnology, but investors have become pickier. They're backing companies with tangible science, real unit economics and a clear path to revenue, and they are writing fewer cheques.

Most investors in RNA-based crop protection also know the GreenLight Biosciences story. The company listed through a SPAC in early 2022 at an enterprise value of about $1.2bn, and in May 2023 agreed to be taken private by a consortium led by Fall Line at roughly $45.5m. Later that year it won the first US EPA registration of a sprayable RNA insecticide, Calantha, for Colorado potato beetle, after more than four years of review. By 2025 it had closed a Series C that included $25m from Just Climate and signed up to €35m of venture debt with the European Investment Bank.

For investors the takeaway is about time. Approvals take years, regulators set the pace, and the balance sheet has to last until then. Any company raising in this space will be asked how its financing avoids the same trap.

2. The situation

The company had many of the things investors look for: more than ten years of operating history, patents in several jurisdictions, field data, grant funding, and global corporates paying to co-develop products. It wanted a bridge to reach a Series A.

But the documents it had prepared did not agree with each other. Different versions gave different amounts, different instruments and different Series A dates. Headcount and patent counts varied between sources. None of this suggested bad faith; it is common in companies that have raised in small steps over many years. It did mean that no investor could have priced the bridge as presented.

So the first job was to get to one set of numbers, each tied to a source document, before any investor saw anything.

3. Why a discount-only note does not work here

The simplest bridge is a convertible note or SAFE that converts into the next round at a discount. It works when the next round is close and well defined. When it isn't, you run into three problems.

• No ceiling. Without a valuation cap, a strong Series A leaves the bridge investor with only the discount, even though they took the earlier and larger risk.
• No end date. Without a maturity and a default conversion price, the investor has no answer to the question of what happens if the Series A never comes.
• No ranking. If the company already has convertible debt or short-term loans, the new money needs to know where it sits and whether it is being used to repay them.

The cap is the term that matters most. The table below uses round, made-up numbers (not the client's terms) for a note with a 20% discount, with and without a $50m cap.

Illustrative only. Conversion price shown as the effective pre-money valuation at which the note converts.

The cap changes nothing if the Series A is modest, and protects the bridge investor if it is strong. Which is why founders tend to resist it and experienced investors tend to insist on it. If a company really expects a strong Series A, offering a cap shouldn't worry it.

4. Size the bridge to milestones, not to a range

A bridge described only as a wide range, where the top is several times the bottom, tells an investor the company has not decided what the money is for. It's better to list the milestones that will move the Series A valuation, put a date and a cost against each, and size the bridge to reach them with a cash buffer.

For a biological crop-protection company those milestones are usually regulatory-grade field data, a signed commercial or manufacturing partnership, first licence or royalty revenue, and a named Series A lead. A realistic first close is often the amount two to four specialist investors will commit together. A much larger bridge normally needs an anchor, such as a strategic partner or a public co-investor, before anyone else will follow.

5. What the money repays matters

Investors read the use of proceeds closely. New money that funds trials, patents and hiring buys future value. New money that repays short-term debt, especially alongside asset sales, reads as a company funding its past. Both can be legitimate, but they need to be separated and explained. If part of the bridge refinances existing debt, say so plainly, show the lender and maturity, and show that the rest of the round still reaches the milestones.

6. Lead with one product

Platform companies often present every application at once: crop protection, food, cosmetics, animal health, materials. To a bridge investor this raises the question of what the company actually is. It usually works better to lead with the one programme closest to revenue and regulatory approval, and treat the others as partner-funded options that add value without consuming the bridge.

7. Who funds a bridge like this

• Specialist investors first. Agricultural, food and industrial biotechnology funds, and the corporate venture arms of crop protection, ingredient and fermentation groups, who already understand biological timelines.
• Long-horizon private capital. Family offices with agriculture or life-science holdings, and food-security focused capital, including in the Gulf.
• Blended and public capital. Impact funds with a pesticide-reduction thesis, venture debt providers, and public development lenders. The European Investment Bank's venture debt for GreenLight shows public capital will back RNA biologicals once regulatory progress is visible.

The list should be short and specialist. In a sector with a known cautionary tale, a broad generalist process tends to use up credibility before it finds money.

8. Bridge term checklist

• One amount, with a minimum first close and the runway it buys
• One instrument, SAFE or convertible note, with its reasons
• A valuation cap, plus the conversion discount
• Interest or PIK terms, if a note
• A maturity date and a default conversion price if no Series A arrives
• Ranking against existing convertibles and short-term debt
• Use of proceeds, split between new milestones and refinancing
• Dated milestones the bridge will reach before the Series A
• A reconciled data room: accounts, cap table, patents, trial reports
• Written permission for any third-party research shown to investors

9. What this mandate is teaching me

I've come to see a bridge as its own investment with its own risk, rather than an early slice of the Series A, and it needs pricing that way. The companies that raise bridges well stop talking about the round they hope to do next and pin down the one in front of them: how much, on what terms, for which milestones, and what happens if the next round is late. Investors in this sector remember the last company that ran out of time, so that kind of discipline goes a long way.

Sources

1. AgFunder, Global AgriFoodTech Investment Report 2026
2. AgFunderNews, "Agrifoodtech funding is flat but the story is shifting"
3. Fierce Biotech, GreenLight returns to private market in $46M deal (May 2023)
4. GreenLight Biosciences, EPA registration of Calantha
5. Just Climate, GreenLight Series C (March 2025)
6. European Investment Bank, €35 million for GreenLight Biosciences (2025)

This paper is for discussion only and is not investment advice. It draws on a live mandate; the company is not named and no client terms are disclosed. The conversion table uses hypothetical numbers.

Summary

Humanoid robotics is having its biggest funding cycle yet, but the money is going to a small group of companies building general-purpose robots for factories and warehouses. Companies that built humanoids before this cycle often have strong brands, real technology and paying customers, yet they struggle to raise on the same terms.

This paper looks at one such company, an Asia-based humanoid robotics business founded long before the current wave, which needs two different kinds of capital at the same time: short-term money to deliver contracts it has already won, and larger strategic capital to grow. My view is that these should be run as two separate raises, each with its own instrument. Fund the contracted work first, then use the delivery record it creates to go after the strategic round from a stronger position.

1. The market: plenty of capital, very concentrated

Source: Tracxn, Humanoid Robotics Report, June 2026.

The headline rounds show where investor attention sits. Figure raised more than $1bn in its Series C at a $39bn post-money valuation in September 2025. Apptronik added a $520m extension in February 2026, taking its Series A past $935m at a valuation reported between $5.3bn and $5.5bn, with Google, Mercedes-Benz, John Deere and the Qatar Investment Authority among its backers. Agility Robotics agreed in June 2026 to go public through a merger with Churchill Capital Corp XI at around $2.5bn, with a $200m PIPE led by Foxconn.

Late-stage money has arrived too, with $1.1bn of late-stage rounds in 2025 and $2bn in the first half of 2026. Corporates are investing as well. Carmakers, farm machinery makers, telecoms groups and contract manufacturers now sit on humanoid cap tables, and that matters for a company that doesn't fit the headline story.

2. The early-generation problem

Investors in this cycle are underwriting one thesis: a general-purpose robot that can do physical work in a factory or warehouse, sold at scale. A company built earlier, for research, entertainment, education or social interaction, gets measured against that thesis and usually loses on it.

So you end up with a company people recognise but new investors find hard to back. It may be well known, hold valuable technology and have customers paying for real projects, but a thin public funding record and a product mix that does not match the dominant thesis make it hard for a new investor to price. In our conversations nobody doubted the technology. What people wanted to know was whether the revenue was contracted and whether it would repeat.

That's useful, because the company doesn't need to win the general-purpose race to raise money. It needs to show that the work it already has turns into cash.

3. Two needs, two instruments

The most common mistake is to solve both needs with one instrument. Raising equity to cover a short cash gap sells permanent ownership to fix a temporary problem, usually at a weak valuation because the company is raising under pressure. Using short-term debt to fund a long path to scale causes the opposite problem, a refinancing deadline the business can't meet. Most of the work is in matching each instrument to how long the money is needed and how risky its use is.

4. Track A: lending against contracted execution

A bridge lender isn't really looking at the humanoid market. It's looking at a set of contracts, which makes the bridge much easier to raise than the equity, provided the company can show a lender the following.

• A contract register. Every signed order with customer, value, delivery milestones and payment terms.
• Counterparty quality. Who is paying, and how reliably. A receivable from a large institution is worth more than one from a start-up customer.
• Delivery risk. Can the company build what it sold on time? Lenders will ask about component supply, production capacity and past delivery.
• Margin per contract. The lender wants to know the contracts are profitable once delivered, not just large.
• Clean security. Which receivables and inventory the lender can take, and what stays free.

Lenders typically advance a percentage of eligible receivables or of the cost to deliver a confirmed order, rather than the full contract value, so the bridge should be sized to the contracted book rather than to what the company would like. It will cost more than bank debt, which is fine for money that is short-term, repays itself and doesn't dilute shareholders ahead of the strategic round.

The point I'd stress most is security. The bridge must not take a charge over the assets a strategic investor will want, especially the intellectual property. A bridge that pledges the IP can quietly kill the Track B conversation.

5. Track B: selling the scarce capability

For the strategic raise, pitching the company as yet another general-purpose humanoid would be a mistake. It's better to lead with whatever is genuinely scarce in its technology and find the buyer who values that most. For an early-generation company this is often human-robot interaction: expressive faces, conversation, and years of real-world deployment data in settings the new entrants have not reached.

That opens four routes:

• Specialist growth equity from robotics and deep-tech funds that understand hardware timelines.
• A strategic investor, such as a manufacturer, component supplier or platform company, that gains access to the technology. The Apptronik and Agility cap tables show corporates are actively doing this.
• Licensing or partnership of specific technology to a larger humanoid maker, bringing in cash without selling the company.
• A strategic transaction. Tracxn records five strategic acquisitions in humanoid robotics since early 2025. For some early-generation companies a sale to a larger player may create more value than a standalone round.

The question to put to every potential investor is the one that drives good sell-side work: who is this company worth more to than its standalone financials suggest?

6. Sequencing: why the bridge comes first

Running the tracks in order changes the negotiation. Once the bridge funds delivery, the company can show contracts turning into cash, which is the evidence growth investors asked us for. It also removes the time pressure that pushes companies into poor equity terms.

1. Weeks 1 to 3. Build the contract register, receivables ageing and delivery plan. Size the bridge to the contracted book.
2. Weeks 3 to 8. Close the bridge with a lender whose security leaves the IP free.
3. Months 2 to 6. Deliver, collect, and use the delivery record to run the strategic process across equity, strategic and transaction routes in parallel.

The risk to manage is overlap. If the strategic process starts while delivery is still uncertain, investors will price the uncertainty. I'd rather spend a few extra weeks on delivery and walk into the strategic conversation with proof.

7. Readiness checklist

Before either track goes to market, the company should have:

• A contract and order register with payment terms and milestones
• Receivables ageing and customer payment history
• A delivery schedule with component supply and production capacity
• Unit economics per robot or per project
• An IP register showing what is owned, licensed and pledged
• A clean cap table and a record of all past funding
• A use-of-funds plan split between Track A and Track B
• A map of lenders, investors and strategic buyers for each track

8. What this mandate is teaching me

The main thing I've taken from this mandate is that a well-known brand doesn't raise money on its own. Investors want evidence, and the quickest way to produce it is often a smaller, well-structured raise that turns existing contracts into cash. When most of the capital is going to a handful of names, companies outside that group do better by being precise about what each dollar is for and by raising each kind of capital from the people best placed to price it.

Sources

1. Tracxn, Humanoid Robotics Report (June 2026)
2. Figure, "Figure Exceeds $1B in Series C Funding at $39B Post-Money Valuation" (September 2025)
3. CNBC, "Apptronik raises $520 million at $5 billion valuation" (February 2026)
4. Crunchbase News, Apptronik Series A extension (February 2026)
5. TechCrunch, "Agility Robotics plans to go public via SPAC in a $2.5B deal" (June 2026)
6. Tangible, Hardtech's Debt-Raising Map

This paper is for discussion only and is not investment advice. It draws on a live mandate; the company is not named and no client terms are disclosed.